116th CONGRESS 1st Session

To amend title XI of the Social Security Act to reauthorize the Patient-Centered Outcomes Research Institute, and for other purposes.

IN THE SENATE OF THE UNITED STATES

Mr. WARNER (for himself, Mr. CASSIDY, Mr. VAN HOLLEN, and Mrs. CAPITO) introduced the following bill; which was read twice and referred to the Committee on ______

A BILL

- To amend title XI of the Social Security Act to reauthorize the Patient-Centered Outcomes Research Institute, and for other purposes.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

- 4 This Act may be cited as the "Patient-Centered Out-
- 5 comes Research Institute Reauthorization Act".

6 SEC. 2. REAUTHORIZATION OF PATIENT-CENTERED OUT-

7

COMES RESEARCH INSTITUTE.

8 (a) EXTENSION OF FUNDING.—

1	(1) MANDATORY APPROPRIATIONS.—Section
2	9511 of the Internal Revenue Code of 1986 is
3	amended—
4	(A) in subsection $(b)(1)(E)$, by striking
5	"2014" and all that follows through "2019"
6	and inserting "2014 through 2029";
7	(B) in subsection $(d)(2)(A)$, by striking
8	"2019" and inserting "2029"; and
9	(C) in subsection (f), by striking "2019"
10	and inserting "2029".
11	(2) EXTENSION OF MEDICARE TRANSFERS.—
12	Section $1183(a)(2)$ of the Social Security Act (42)
13	U.S.C. 1320e–2(a)(2)) is amended by striking
14	"2014" and all that follows through "2019" and in-
15	serting "2014 through 2029".
16	(3) EXTENSION OF CERTAIN HEALTH INSUR-
17	ANCE FEES.—
18	(A) Health insurance policies.—Sec-
19	tion 4375(e) of the Internal Revenue Code of
20	1986 is amended by striking "2019" and in-
21	serting "2029".
22	(B) Self-insured health plans.—Sec-
23	tion 4376(e) of the Internal Revenue Code of
24	1986 is amended by striking "2019" and in-
25	serting "2029".

1	(b) BOARD COMPOSITION.—Subsection (f) of section
2	1181 of the Social Security Act (42 U.S.C. 1320e) is
3	amended—
4	(1) in paragraph (1) —
5	(A) in subparagraph (C)—
6	(i) in the matter preceding clause
7	(i)—
8	(I) by striking "Seventeen" and
9	inserting "Twenty-three"; and
10	(II) by striking ", not later than
11	6 months after the date of enactment
12	of this section,"; and
13	(ii) in clause (iii), by striking "3" and
14	inserting "7"; and
15	(2) in paragraph (3)—
16	(A) in the first sentence—
17	(i) by striking the "the members" and
18	inserting "members"; and
19	(ii) by inserting the following before
20	the period at the end: "to the extent nec-
21	essary to preserve the evenly staggered
22	terms of the Board."; and
23	(B) by inserting the following after the
24	first sentence: "Any member appointed to fill a
25	vacancy occurring before the expiration of the

2appointed shall be appointed for the remainder3of that term and thereafter may be eligible for4reappointment to a full term. A member may5serve after the expiration of that member's6term until a successor has been appointed.".7(c) CONSIDERATION OF FULL RANGE OF OUTCOMES8DATA.—Subsection (d)(2) of such section 1181 is amend-9ed by adding at the end the following subparagraph:10"(F) CONSIDERATION OF FULL RANGE OF11OUTCOMES DATA.—Research shall be designed,12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and elinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket25costs, including health plan benefit and for-	1	term for which the member's predecessor was
4reappointment to a full term. A member may serve after the expiration of that member's term until a successor has been appointed.".7(c) CONSIDERATION OF FULL RANGE OF OUTCOMES 8 DATA.—Subsection (d)(2) of such section 1181 is amend- 9 ed by adding at the end the following subparagraph:10"(F) CONSIDERATION OF FULL RANGE OF 11 OUTCOMES DATA.—Research shall be designed, as appropriate, to take into account and cap- ture the full range of clinical and patient-cen- tered outcomes relevant to, and that meet the needs of, patients, clinicians, purchasers, and policy-makers in making informed health deci- sions. In addition to the relative health out- comes and clinical effectiveness, clinical and pa- tient-centered outcomes shall include the poten- tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket	2	appointed shall be appointed for the remainder
5serve after the expiration of that member's6term until a successor has been appointed.".7(e) CONSIDERATION OF FULL RANGE OF OUTCOMES8DATA.—Subsection (d)(2) of such section 1181 is amend-9ed by adding at the end the following subparagraph:10"(F) CONSIDERATION OF FULL RANGE OF11OUTCOMES DATA.—Research shall be designed,12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	3	of that term and thereafter may be eligible for
6term until a successor has been appointed.".7(c) CONSIDERATION OF FULL RANGE OF OUTCOMES8DATA.—Subsection (d)(2) of such section 1181 is amend-9ed by adding at the end the following subparagraph:10"(F) CONSIDERATION OF FULL RANGE OF11OUTCOMES DATA.—Research shall be designed,12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	4	reappointment to a full term. A member may
7(c) CONSIDERATION OF FULL RANGE OF OUTCOMES8DATA.—Subsection (d)(2) of such section 1181 is amend-9ed by adding at the end the following subparagraph:10"(F) CONSIDERATION OF FULL RANGE OF11OUTCOMES DATA.—Research shall be designed,12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	5	serve after the expiration of that member's
 8 DATA.—Subsection (d)(2) of such section 1181 is amend- 9 ed by adding at the end the following subparagraph: 10 "(F) CONSIDERATION OF FULL RANGE OF 11 OUTCOMES DATA.—Research shall be designed, 12 as appropriate, to take into account and cap- 13 ture the full range of clinical and patient-cen- 14 tered outcomes relevant to, and that meet the 15 needs of, patients, clinicians, purchasers, and 16 policy-makers in making informed health deci- 17 sions. In addition to the relative health out- 18 comes and clinical effectiveness, clinical and pa- 19 tient-centered outcomes shall include the poten- 20 tial burdens and economic impacts of the utili- 21 zation of medical treatments, items, and serv- 22 ices on different stakeholders and decision-mak- 23 ers respectively. These potential burdens and 24 economic impacts include medical out-of-pocket 	6	term until a successor has been appointed.".
 9 ed by adding at the end the following subparagraph: "(F) CONSIDERATION OF FULL RANGE OF OUTCOMES DATA.—Research shall be designed, as appropriate, to take into account and cap- ture the full range of clinical and patient-cen- tered outcomes relevant to, and that meet the needs of, patients, clinicians, purchasers, and policy-makers in making informed health deci- sions. In addition to the relative health out- comes and clinical effectiveness, clinical and pa- tient-centered outcomes shall include the poten- tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket 	7	(c) Consideration of Full Range of Outcomes
10 "(F) CONSIDERATION OF FULL RANGE OF 11 OUTCOMES DATA.—Research shall be designed, 12 as appropriate, to take into account and cap- 13 ture the full range of clinical and patient-cen- 14 tered outcomes relevant to, and that meet the 15 needs of, patients, clinicians, purchasers, and 16 policy-makers in making informed health deci- 17 sions. In addition to the relative health out- 18 comes and clinical effectiveness, clinical and pa- 19 tient-centered outcomes shall include the poten- 20 tial burdens and economic impacts of the utili- 21 zation of medical treatments, items, and serv- 22 ices on different stakeholders and decision-mak- 23 ers respectively. These potential burdens and 24 economic impacts include medical out-of-pocket	8	DATA.—Subsection (d)(2) of such section 1181 is amend-
11OUTCOMES DATA.—Research shall be designed,12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	9	ed by adding at the end the following subparagraph:
12as appropriate, to take into account and cap-13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	10	"(F) Consideration of full range of
13ture the full range of clinical and patient-cen-14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	11	OUTCOMES DATA.—Research shall be designed,
14tered outcomes relevant to, and that meet the15needs of, patients, clinicians, purchasers, and16policy-makers in making informed health deci-17sions. In addition to the relative health out-18comes and clinical effectiveness, clinical and pa-19tient-centered outcomes shall include the poten-20tial burdens and economic impacts of the utili-21zation of medical treatments, items, and serv-22ices on different stakeholders and decision-mak-23ers respectively. These potential burdens and24economic impacts include medical out-of-pocket	12	as appropriate, to take into account and cap-
15 needs of, patients, clinicians, purchasers, and 16 policy-makers in making informed health deci- 17 sions. In addition to the relative health out- 18 comes and clinical effectiveness, clinical and pa- 19 tient-centered outcomes shall include the poten- 20 tial burdens and economic impacts of the utili- 21 zation of medical treatments, items, and serv- 22 ices on different stakeholders and decision-mak- 23 ers respectively. These potential burdens and 24 economic impacts include medical out-of-pocket	13	ture the full range of clinical and patient-cen-
policy-makers in making informed health deci- sions. In addition to the relative health out- comes and clinical effectiveness, clinical and pa- tient-centered outcomes shall include the poten- tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket	14	tered outcomes relevant to, and that meet the
 sions. In addition to the relative health out- comes and clinical effectiveness, clinical and pa- tient-centered outcomes shall include the poten- tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket 	15	needs of, patients, clinicians, purchasers, and
 comes and clinical effectiveness, clinical and pa- tient-centered outcomes shall include the poten- tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket 	16	policy-makers in making informed health deci-
 19 tient-centered outcomes shall include the poten- 20 tial burdens and economic impacts of the utili- 21 zation of medical treatments, items, and serv- 22 ices on different stakeholders and decision-mak- 23 ers respectively. These potential burdens and 24 economic impacts include medical out-of-pocket 	17	sions. In addition to the relative health out-
 tial burdens and economic impacts of the utili- zation of medical treatments, items, and serv- ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket 	18	comes and clinical effectiveness, clinical and pa-
 21 zation of medical treatments, items, and serv- 22 ices on different stakeholders and decision-mak- 23 ers respectively. These potential burdens and 24 economic impacts include medical out-of-pocket 	19	tient-centered outcomes shall include the poten-
 ices on different stakeholders and decision-mak- ers respectively. These potential burdens and economic impacts include medical out-of-pocket 	20	tial burdens and economic impacts of the utili-
ers respectively. These potential burdens andeconomic impacts include medical out-of-pocket	21	zation of medical treatments, items, and serv-
24 economic impacts include medical out-of-pocket	22	ices on different stakeholders and decision-mak-
	23	ers respectively. These potential burdens and
25 costs, including health plan benefit and for-	24	economic impacts include medical out-of-pocket
	25	costs, including health plan benefit and for-

1	mulary design, non-medical costs to the patient
2	and family, including caregiving, effects on fu-
3	ture costs of care, workplace productivity and
4	absenteeism, and healthcare utilization.".
5	(d) Establishment of Expert Advisory
6	PANEL.—Subsection (d)(4)(A) of such section 1181 is
7	amended by adding at the end the following new clause:
8	"(iv) EXPERT ADVISORY PANEL FOR
9	HIGH-IMPACT RESEARCH.—The Institute
10	shall appoint an expert advisory panel for
11	purposes of assisting and advising the In-
12	stitute on ways to take into account and
13	target diseases, conditions, and care inter-
14	ventions that have a high-impact on na-
15	tional health expenditures and advance the
16	incorporation of practical evidence into
17	health care delivery in the national prior-
18	ities for research and the research project
19	agenda under paragraph (1). Such panel
20	shall include members representing private
21	and public payers in addition to the com-
22	position requirements described in sub-
23	paragraph (B).".
24	(e) Ensuring Coverage for Clinical Trials
25	UNDER EXISTING STANDARD OF CARE.—

1	(1) REVISION TO DEFINITION OF APPROVED
2	CLINICAL TRIAL IN INDIVIDUAL AND GROUP MAR-
3	КЕТ.—
4	(A) IN GENERAL.—Subsection $(d)(1)$ of
5	the first section 2709 of the Public Health
6	Service Act (42 U.S.C. 300gg–8) is amended by
7	adding at the end the following new subpara-
8	graph:
9	"(D) The study or investigation is ap-
10	proved or funded (which may include funding
11	through in-kind contributions) by the Patient-
12	Centered Outcomes Research Institute estab-
13	lished under section 1181 of the Social Security
14	Act.".
15	(B) Applicability date.—The amend-
16	ment made by this paragraph shall apply with
17	respect to plan years beginning on or after Jan-
18	uary 1, 2020.
19	(2) Medicare coverage of routine costs
20	ASSOCIATED WITH CERTAIN CLINICAL TRIALS.—
21	(A) IN GENERAL.—Section $1862(m)(2)$ of
22	the Social Security Act (42 U.S.C.
23	1395y(m)(2)) is amended, in the matter pre-
24	ceding subparagraph (A), by inserting "(includ-
25	ing a trial funded by the Patient-Centered Out-

1	comes Research Institute established under sec-
2	tion 1181)" after "means a trial".
3	(B) EFFECTIVE DATE.—The amendment
4	made by this subparagraph shall apply with re-
5	spect to items and services furnished on or
6	after the date of the enactment of this Act.
7	(f) Additions to Annual Reports by the Insti-
8	TUTE.—Subsection (d)(10)(A) of such section 1181 is
9	amended—
10	(1) by inserting ", including narrative state-
11	ments of funding announcements of the Institute,"
12	after "paragraph (1)(A)"; and
13	(2) by inserting the following before the semi-
14	colon: "as well as any barriers that researchers
15	funded by the Institute have encountered in con-
16	ducting studies or clinical trials, including challenges
17	covering the cost of any medical treatments, serv-
18	ices, and items described in subsection $(a)(2)(B)$ for
19	purposes of the research study".
20	(g) GAO OVERSIGHT.—Subsection (g)(2)(A) of such
21	section 1181 is amended by adding at the end the fol-
22	lowing new clause:
23	"(vi) Not less frequently than every 5
24	years, any barriers that researchers funded
25	by the Institute have encountered in con-

KEL19896

8

1	ducting studies or clinical trials, including
2	challenges covering the cost of any medical
3	treatments, services, and items described
4	in subsection $(a)(2)(B)$ for purposes of the
5	research study.".
6	(h) AGENCY FOR HEALTHCARE RESEARCH AND
7	QUALITY ACTIVITIES.—
8	(1) Implementation of research find-
9	INGS.—Section 937(b) of the Public Health Service
10	Act (42 U.S.C. 299b-37(b)) is amended to read as
11	follows:
12	"(b) Implementation.—The Agency for Healthcare
13	Research and Quality, in consultation with relevant med-
14	ical and clinical associations, shall carry out activities to
15	promote the timely implementation of research findings
16	disseminated under subsection (a) into clinical practices,
17	including by assisting users of health information tech-
18	nology focused on clinical decision support in such imple-
19	mentation, in order to improve quality of care, health out-
20	comes, and population health and to promote the ease of
21	use of such implementation.".

(2) PAPERWORK REDUCTION ACT.—Section 937
of the Public Health Service Act (42 U.S.C. 299b–
37) is amended by adding at the end the following:

1	"(h) Administration.—Chapter 35 of title 44,
2	United States Code, shall not apply to any activity carried
3	out under this section.".
4	(3) Office of communication and knowl-
5	EDGE TRANSFER.—
6	(A) IN GENERAL.—Section 937 of the
7	Public Health Service Act (42 U.S.C. 299b–
8	37), as amended by paragraph (1), is further
9	amended—
10	(i) in subsection $(a)(1)$, by striking
11	"The Office of Communication and Knowl-
12	edge Transfer'' and all that follows
13	through "Healthcare Research and Qual-
14	ity)" and inserting "The Agency for
15	Healthcare Research and Quality"; and
16	(ii) by striking "Office" each place it
17	appears and inserting "Agency for
18	Healthcare Research and Quality".
19	(B) PATIENT-CENTERED OUTCOMES RE-
20	SEARCH TRUST FUND.—Section
21	9511(d)(2)(C)(i) of the Internal Revenue Code
22	of 1986 is amended by striking "the Office of
23	Communication and Knowledge Transfer" and
24	all that follows through "Healthcare Research

KEL19896

10

and Quality)" and inserting "the Agency for
 Healthcare Research and Quality".

3 (i) PROMOTION OF TIMELY IMPLEMENTATION OF
4 RESEARCH FINDINGS.—Subsection (c) of such section
5 1181 is amended by inserting "and promotion of the time6 ly implementation" after "dissemination".

7 (j) IDENTIFICATION OF RESEARCH PRIORITIES.—
8 Subsection (d)(1)(A) of such section 1181 is amended by
9 adding at the end the following new sentence: "Such prior10 ities should reflect a balance between long-term priorities
11 and short-term priorities, and be responsive to changing
12 medical evidence and health care treatments.".

13 (k) EFFECTIVE DATE.—Except as otherwise pro14 vided in this section, the provisions of, and the amend15 ments made by, this section shall take effect on the date
16 of the enactment of this Act.